Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous anti-CD19 CAR T-cells (University Hospital, Montpellier)
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Universitaire de Montpellier
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed by the University Hospital, Montpellier for the treatment of systemic sclerosis (SSc). The therapy involves collecting a patient's T-cells via leukapheresis, genetically modifying them using a lentiviral vector to express a CAR targeting the CD19 antigen found on B-cells, and re-infusing the cells following lymphodepleting chemotherapy. This approach aims to achieve a deep and durable depletion of B-cells, potentially resetting the immune system and halting the autoimmune and fibrotic processes characteristic of severe, treatment-resistant systemic sclerosis. The product is currently being evaluated in the Phase IIa SCLEROCAR clinical trial.
- Other names
- anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19 CAR T-cellsCD-19 CAR T-cellsCD 19 CAR T-cells
02
Targets
Beyond the preview
Go deeper on autologous anti-CD19 CAR T-cells (University Hospital, Montpellier).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous anti-CD19 CAR T-cells (University Hospital, Montpellier).